# Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

> clinical trial · VERIFIED · 2026-07-08

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Grade 1 Follicular Lymphoma

- Company: National Cancer Institute (NCI)
- Sector: Grade 1 Follicular Lymphoma
- Primary source: https://clinicaltrials.gov/study/NCT03269669

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.